The role of somatostatin and dopamine receptors as molecular targets for the treatment of
patients with pituitary adenomas is well established. Indeed, dopamine and somatostatin …

The role of somatostatin and dopamine receptors as molecular targets for the treatment of
patients with pituitary adenomas is well established. Indeed, dopamine and somatostatin …

Dopamine and somatostatin receptor agonists inhibit hormone secretion by normal pituitary
cells and pituitary adenomas. Indeed, initially several dopaminergic drugs, and lately …

The discovery of the new properties of SSRs and DRs has led to a renewed interest in
agents targeting these receptors and has opened new perspectives for medical treatment of …

The patho-physiological role of somatostatin receptor subtypes (sst) in neuro endocrine
diseases has gained enhanced scientific interest in the past few years. The development of …

The discovery of the new properties of somatostatin (SSTRs) and dopamine (DRs) receptors
has led to a renewed interest in agents targeting these receptors, and has opened new …

Somatostatin is a tetradecapeptide widely distributed throughout the central nervous system
and peripheral tissues [1]. It is a physiological inhibitor of pituitary GH and TSH secretion …

Introduction: Somatostatin and dopamine receptors are both G-protein-coupled receptors.
Somatostatin receptor (SSTR) expression in neuroendocrine tumours has been well …

Dopamine and somatostatin are both involved in the negative control of normal pituitary
cells. Dopamine subtype 2 receptor (D2DR) and somatostatin receptor (sst) agonists, mainly …

Aim: We report the comparative efficacy of octreotide, cabergoline and multiple ligands
directed towards the different somatostatin subtypes (ssts), such as BIM-23A779 and SOM …